Ping‐Chih Hsu

机构：Memorial Hospital of South Bend, Chang Gung University, Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital · ORCID：0000-0003-0173-7509

发表论文 96 篇 · 总被引 1767 次 · h-index 21

代表论文

• Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study (2024 · Journal of Clinical Oncology · 被引 127)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 19)
• The antitumor activity of osimertinib plus palbociclib in non-small cell lung cancer patient-derived xenograft (PDX)/2D/3D culture models harboring EGFR amplification and CDKN2A/2B homozygous deletions (2024 · Neoplasia · 被引 9)
• Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis (2025 · Oncology Letters · 被引 6)
• A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer (2024 · Vaccines · 被引 6)
• Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity (2024 · The Journal of Allergy and Clinical Immunology In Practice · 被引 5)